Status:
RECRUITING
Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
Lead Sponsor:
International Consortium of Circulatory Assist Clinicians
Collaborating Sponsors:
Abbott
Medical University of Vienna
Conditions:
LVAD
Frailty
Eligibility:
All Genders
18-100 years
Brief Summary
Durable left ventricular assist devices (dLVAD) have been increasingly utilized since the mid to late 1990s, with an uptick of utility starting in 2010 following expanded indications for therapy to no...
Detailed Description
Specific Aims The prevalence of heart failure (HF), a chronic medical condition, continues to grow exponentially, affecting more than 26 million globally. There are more than 6.5 million in the United...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Scheduled Heartmate 3 ® dLVAD implantation
Exclusion
- \<18 years of age
- Scheduled for dLVAD that is NOT a Heartmate 3 (R) device
Key Trial Info
Start Date :
October 27 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06039176
Start Date
October 27 2023
End Date
December 30 2026
Last Update
December 16 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF
San Francisco, California, United States, 94143
2
University of Florida
Gainesville, Florida, United States, 32611
3
University of Chicago
Chicago, Illinois, United States, 60637
4
University of Kansas Medical Center
Kansas City, Kansas, United States, 66103